INSM Stock — Insmed Incorporated

Insmed Incorporated (INSM)

Updated October 16, 2026.

INSM is a Stock. Total return is 1066.9% over the past 35.7 years.

Insmed Incorporated is a biopharmaceutical company that develops and commercializes therapies for serious and rare diseases, including respiratory and genetic conditions. Its commercial product ARIKAYCE treats refractory nontuberculous mycobacterial lung infections, while its pipeline includes several late-stage candidates: brensocatib for bronchiectasis, treprostinil palmitil inhalation powder for pulmonary hypertension, and gene therapy programs for Duchenne muscular dystrophy and amyotrophic lateral sclerosis, among other programs. The company does not currently distribute to shareholders.

INSM performance

Price and return data through 2026-10-16.

Total return is 1066.9% over the past 35.7 years. Over the past year its total return — price change plus distributions reinvested — is -41.0%. Its deepest 1-year drawdown was 56.5%.

INSM key facts

Asset type

Stock

Asset class

Equity

Inception date

02/15/1991

Distribution frequency

None

Last close

$96.27 (as of 2026-10-16)

Market cap

$21,023,587,294

Average volume

2395752.0

Beta

0.824

Payout ratio

0.0%

Forward P/E

97.0874

EPS

$-4.10

How Dividend Vision calculates yield and returns

Distribution rate (the posted rate) uses calculation basis unavailable. Issuer rates can use a different denominator and date, including ex-date NAV. Trailing-12-month yield is the sum of split-adjusted cash distributions with ex-dates in the last 12 months, divided by the published price. It lags a recent raise or cut. Total return uses split-adjusted close with distributions reinvested on the ex-dividend date (a modeling convention, not the cash-settlement date) from the first stored bar on or after inception through the latest bar, compared with the same window on the benchmark. That is the security's total return, not your personal gain/loss.

Yield and safety methodology · Distribution rate methodology · Distribution Safety Score methodology

Sources and review

Primary sources: prices and distributions from Dividend Vision, derived from vendor EOD data.

Reviewed by Bert Sweet, CEO and Co-owner of Dividend Vision. Methodology: Distribution Safety Score.

INSM risks and drawbacks

The deepest 1-year drawdown on record here is 56.5%.

Who may consider INSM — and who may not

It is a weaker fit for investors who need monthly cash flow (INSM does not currently distribute). This is educational context, not a recommendation to buy or sell.

More on INSM

• All tickers starting with I

Tagged: Healthcare.

Frequently asked questions